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A B S T R A C T
Pulmonary delivery of macromolecules has been the focus of attention as an alternate route of delivery
with beneﬁts such as; large surface area, thin alveolar epithelium, rapid absorption and extensive
vasculature. In this study, a model protein, bovine serum albumin (BSA) was adsorbed onto cationic PGA-
co-PDL polymeric nanoparticles (NPs) prepared by a single emulsion solvent evaporation method using a
cationic surfactant didodecyldimethylammonium bromide (DMAB) at 2% w/w (particle size:
128.64  06.01 nm and zeta-potential: +42.32  02.70 mV). The optimum cationic NPs were then surface
adsorbed with BSA, NP:BSA (100:4) ratio yielded 10.01 1.19 mg of BSA per mg of NPs. The BSA adsorbed
NPs (5 mg/ml) were then spray-dried in an aqueous suspension of L-leucine (7.5 mg/ml, corresponding to
a ratio of 1:1.5/NP:L-leu) using a Büchi-290 mini-spray dryer to produce nanocomposite microparticles
(NCMPs) containing cationic NPs. The aerosol properties showed a ﬁne particle fraction (FPF,
dae < 4.46 mm) of 70.67 4.07% and mass median aerodynamic diameter (MMAD) of 2.80  0.21 mm
suggesting a deposition in the respiratory bronchiolar region of the lungs.The cell viability was
75.76  03.55% (A549 cell line) at 156.25 mg/ml concentration after 24 h exposure. SDS-PAGE and circular
dichroism (CD) conﬁrmed that the primary and secondary structure of the released BSA was maintained.
Moreover, the released BSA showed 78.76  1.54% relative esterolytic activity compared to standard BSA.
ã 2015 Published by Elsevier B.V.
9 1. Introduction
10 An increase in mortality and morbidity associated with
11 pulmonary diseases has led to the exploration of pulmonary drug
12 delivery as a non-invasive approach for the treatment and
13 management of these diseases and also for administration of
14 therapeutics for systemic delivery (Carlotta et al., 2011; Yang et al.,
15 2008). The lung as a delivery route offers a large surface area (80–
16 90 sq m), extensive vasculature, a thin alveolar epithelium (0.1–
17 0.5 mm) leading to rapid absorption (Scheuch et al., 2006). It is also
18believed that compared to any other entry portal in the body, the
19pulmonary epithelia appears to be more permeable to macro-
20molecules (Patton, 1996). Advancements in biotechnology in the
21last decade have led to the development of new therapeutics such
22as peptides, proteins and other macromolecules (Sullivan et al.,
232006). Despite barriers such as the respiratory mucus, mucociliary
24clearance, macrophages, enzymes and basement membrane that
25limit absorption (Agu et al., 2001), several macromolecules have
26been extensively investigated such as insulin (Al-Qadi et al., 2012;
27Kling, 2014), bovine serum albumin (BSA) (Jiang et al., 2010; Kunda
28et al., 2014), calcitonin (Yamamoto et al., 2005) for delivery via the
29pulmonary route. Q2
30Biodegradable nanoparticles (NPs), are being explored for the
31delivery of macromolecules as they offer improved bioavailability,
32controlled or sustained release and biocompatibility (Kumari et al.,
332010; Tawfeek et al., 2011). Several factors such as polymer
34properties, size and charge of NPs, and the stabilizer(s) employed
35in the preparation of NPs play a vital role in determining their
36uptake, biodistribution, drug loading and fate after administration,
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37 all of which affect the therapeutic efﬁcacy (Bhardwaj et al., 2009;
38 Peetla and Labhasetwar, 2009). Herein, we used a cationic
39 surfactant, quaternary ammonium salt didodecyldimethyl ammo-
40 nium bromide (DMAB) to produce positively charged NPs. It is
41 established that the cationic surfactant DMAB produces small,
42 stable NPs and prevents particle agglomeration (Bhardwaj et al.,
43 2009; Chen et al., 2010; Hariharan et al., 2006; Kwon et al., 2001).
44 The particle size and surface charge of NPs are known to play an
45 important role in determining the cellular uptake, and cationic NPs
46 compared to anionic NPs (negatively charged) or neutral NPs, have
47 better interactions with the negatively charged cell membrane
48 thereby improving their cellular uptake (Hariharan et al., 2006;
49 Peetla and Labhasetwar, 2009). NPs and protein can be attached
50 together either by simple physical adsorption based on charge or
51 hydrophobic interactions (Mody et al., 2013; Wendorf et al., 2006),
52 or complex processes; such as chemical conjugation and encapsu-
53 lation (Zhao et al., 2014). The encapsulation of proteins may
54 present some problems such as low loading and loss of protein
55 activity due to harsh formulation conditions; such as interaction
56 with organic solvents and the higher stirring speed employed in
57 the NP preparation process (Bramwell and Perrie, 2006; Jiang et al.,
58 2005). Alternatively, an adsorption process avoids protein contact
59 with the harsh conditions offering enhanced stability over
60 encapsulated proteins hence providing a promising alternative
61 for encapsulation (Bramwell and Perrie, 2006; Florindo et al.,
62 2010).
63 Due to their small size and low inertia NPs are exhaled after
64 inhalation resulting in low doses in the lungs, and the high surface
65 energy promotes aggregation making them difﬁcult to handle
66 (Stevanovic and Uskokovic, 2009; Yang et al., 2008). Therefore, the
67 NPs to be used in pulmonary delivery are required to be formulated
68 into microcarriers for ideal aerosolisation properties (Sinsuebpol
69 et al., 2013). This can be achieved using excipients, such as lactose,
70 mannitol, trehalose and L-leucine (L-leu) to produce nanocompo-
71 site microparticles (NCMPs) that encompass NPs in a microcarrier
72 (Li et al., 2005; Seville et al., 2007). The NCMPs are formulated
73 using manufacturing techniques such as freeze-drying, spray-
74 drying (SD), spray-freeze drying or supercritical ﬂuid technologies
75 (Al-fagih et al., 2011; Kunda et al., 2013). The aim of this study was
76 to produce cationic NPs with surface adsorbed BSA, and formulate
77 the NPs into NCMPs via SD using L-leu as a carrier for dry powder
78 inhalation.
79 2. Materials and methods
80 2.1. Materials
81 Bovine serum albumin (BSA, MW 67 KDa), didodecyl dimethyl
82 ammonium bromide (DMAB), phosphate buffered saline (PBS, pH
83 7.4) tablets, poly(vinyl alcohol) (PVA, MW 9–10 K, 80%), RPMI-
84 1640 medium with L-glutamine and NaHCO3, thiazoly blue
85 tetrazolium bromide (MTT), tween 801 and 4-nitophenyl acetate
86 were obtained from Sigma–Aldrich, UK. L-leucine (L-leu) was
87 purchased from BioUltra, Sigma, UK. Tissue culture ﬂasks (75 cm2)
88 with vented cap, 96-well ﬂat bottom plates, acetone, acetonitrile
89 (ACN, HPLC grade), antibiotic/antimycotic Solution (100X),
90 dichloromethane (DCM), dimethyl sulfoxide (DMSO) were pur-
91 chased from Fisher Scientiﬁc, UK. Divinyladipate was obtained
92 from Fluorochem, UK. Fetal calf serum (FCS) heat inactivated was
93 purchased from Biosera UK. Micro BCATM protein assay kit was
94 purchased from Thermo Scientiﬁc, UK. Poly(glycerol adipate-co-
95 v-pentadecalactone) (PGA-co-PDL, MW of 14.7 KDa was synthe-
96 sized in our laboratory at LJMU as previously published by
97 Thompson et al. (Thompson et al., 2006) and human adenocarci-
98 nomic alveolar basal epithelial cell line, A549, was purchased from
99 ATCC.
1002.2. Preparation of nanoparticles
101The cationic NPs were prepared using a previously established
102oil-in-water (o/w) single emulsion solvent evaporation method
103(Kunda et al., 2014). Brieﬂy, PGA-co-PDL, (200 mg), (Nile Red, NR,
1040.5 mg for confocal microscopy) and DMAB (0, 1 and 2% w/w of
105polymer) were dissolved in 2 ml DCM and upon addition to 5 ml of
1065% w/v poly(vinyl alcohol) (PVA) was probe sonicated (20 microns
107amplitude) for 2 min under ice to obtain an emulsion. This was
108immediately added drop wise to 20 ml of 0.75% w/v PVA under
109magnetic stirring at a speed of 500 RPM. This mixture was left
110stirring at room temperature for 3 h to facilitate the evaporation of
111DCM. The NP suspension was collected using centrifugation
112(78,000  g, 40 min, 4 C), washing twice to remove unbound
113and excess surfactant. The NPs were then surface adsorbed with
114protein as described in Section 2.3.
1152.3. Protein adsorption and quantiﬁcation
116The NP suspension (equivalent to 10 mg) was resuspended in
1174 ml of BSA (or FITC-BSA for confocal microscopy) at different NP:
118BSA ratios (100:4–100:20) corresponding to 100–500 mg/ml BSA.
119After 1 h of rotation at 20 RPM on a HulaMixerTM Sample Mixer
120(Life Technologies, Invitrogen, UK) the NP suspensions were
121centrifuged and the supernatant analysed for protein content using
122a micro BCA protein assay kit. The amount of BSA adsorbed per
123milligram of NPs (n = 3) was calculated using Eq. (1):
Adsortionðmper mg of NPsÞ ¼
ðInitial protein conc  Supernatant protein concÞ
Amount of NPS
(1)
1242.4. Characterization of nanoparticles
125Morphological analysis of NPs was performed by transmission
126electron microscopy (TEM) using a FEI Morgagni Transmission
127Electron Microscope (Philips Electron Optics BV, Netherlands) at an
128acceleration voltage of 100 kV. Approximately 50 ml of the NP
129suspension was stained with 2% ammonium molybdate and placed
130on a carbon coated copper grid. Digital images were taken at
131magniﬁcation of 44,000 and 110,000.
132Particle size, poly dispersity index (PDI) and surface charge
133(zeta potential) were measured by dynamic laser scattering (DLS)
134using a laser particle size analyser (Zetasizer Nano ZS, Malvern
135Instruments Ltd., UK). An aliquot of 100 ml of the NP suspension
136was diluted with 5 ml of deionized water loaded into a cuvette and
137the measurements recorded at 25 C (n = 3).
1382.5. Preparation of nanocomposite microparticles
139The NPs were incorporated into NCMPs using L-leu as a carrier
140at a weight ratio of 1:1.5 (NP:L-leu). The empty NPs, BSA adsorbed
141NPs or FITC-BSA adsorbed Nile Red NPs (NR NPs for confocal
142microscopy) were dispersed in distilled water containing L-leu at a
143concentration of 12.5 mg/ml (5 mg/ml NPs and 7.5 mg/ml L-leu).
144The resultant suspension was then spray-dried using a Büchi B-
145290 mini spray-dryer (Büchi Labortechnik, Flawil, Switzerland) at a
146feed rate of 10%, an atomizing air ﬂow of 400 L/h, aspirator capacity
147of 100% and an inlet temperature of 100 C (outlet temperature
148approximately 45  2 C). The dry NCMPs were collected from the
149cyclone (Büchi Labortechnik) and stored in a desiccator at room
150temperature until further use.
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151 2.6. Characterization of nanocomposite microparticles
152 2.6.1. Yield, particle size, morphology and moisture content
153 The yield (% w/w) was calculated as the difference in weight
154 before and after collection to the initial total dry mass (n = 3)
155 Particle size and PDI of NPs after re-dispersion of the NCMPs in
156 distilled water were measured to conﬁrm the recovery of NPs from
157 the NCMPs. The measurements were performed as described in
158 Section 2.4, where 5 mg of NCMPs were dispersed in 2 ml of
159 deionized water, loaded into a cuvette and the readings were
160 recorded at 25 C (n = 3).
161 The spray-dried NCMPs were observed under the scanning
162 electron microscope (FEI QuantaTM 200 ESEM, Holland). The
163 samples were mounted onto aluminium pin stubs (13 mm) layered
164 with a sticky conductive carbon tab and coated with palladium
165 (10–15 nm) using a sputter coater (EmiTech K 550X Gold Sputter
166 Coater, 25 mA) before examination under the microscope.
167 Thermo Gravimetric Analysis (TGA) was used to determine the
168 residual moisture content in the spray-dried NCMPs. Measure-
169 ments were carried out in triplicate using a TA Instruments TGA
170 Q50, UK equipped with TA Universal Analysis 2000 software. Solid
171 samples (4–15 mg) were loaded on open platinum TGA pan
172 suspended from a microbalance and heated from 25 to 650 C at
173 10 C per min. The moisture content (water loss) was analysed for
174 data collected between 25 and 120 C.
175 2.7. Characterization of BSA and nanoparticle association
176 To visualise the adsorption of BSA onto the NPs, the spray-dried
177 NCMPs containing FITC-BSA adsorbed NR NPs were observed using
178 a Zeiss 510 Meta confocal laser scanning microscope mounted on
179 an Axiovert 200 M BP inverted microscope. To obtain confocal
180 images, 1–2 mg of spray-dried NCMPs were placed in a single well
181 of an 8-well chambered slide (Fisher Scientiﬁc, UK) and imaged by
182 excitation at a wavelength of 488 nm (green channel for FITC-BSA)
183 and 543 nm (red channel for Nile Red NPs) and with a Plan Neoﬂuar
184 63  / 0.30 numerical aperture objective lens. The obtained
185 confocal images were then analysed using the Zeiss LSM software.
186 2.8. In vitro release studies
187 The NCMPs (20 mg) were weighed into eppendorfs and
188 dispersed in 2 ml of PBS, pH 7.4, and left rotating at a speed of
189 20 RPM on a HulaMixerTM Sample Mixer (Life Technologies,
190 Invitrogen, UK) for 48 h at 37 C. The samples were centrifuged
191 (accuSpin Micro 17, Fisher Scientiﬁc, UK) at 17,000  g for 30 min at
192 pre-determined time intervals ranging from 0, 30 min, 1, 2, 4, 6, 20,
193 24 and 48 h, and 1 ml of the supernatant was removed for analysis
194 and replaced with fresh medium. The supernatant was analysed
195 using the micro BCA protein assay. The percentage cumulative BSA
196 released was calculated using Eq. (2):
%Cumulative BSA released ¼Cumulative BSA released
BSA loaded
 100 (2)
197 2.9. Protein stability and activity
198 2.9.1. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
199 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
200 (SDS-PAGE) was employed to determine the primary structure
201 of BSA. The spray-dried NCMPs, 20 mg, were suspended in 1 ml of
202 2% SDS in HPLC grade water and were rotated on a HulaMixer
TM
203 Sampler Mixer for 48 h. After, the sample was centrifuged
204 (accuSpin Micro 17, Fisher Scientiﬁc, UK) at 17,000  g, 30 min,
205the supernatant was collected and stability of BSA determined. The
206SDS-PAGE was performed on a CVS10D omniPAGE vertical gel
207electrophoresis system (Geneﬂow Limited, UK). A 9% stacking gel
208was prepared using ProtoGel stacking buffer (Geneﬂow Limited,
209UK). The protein loading buffer blue (2) (Geneﬂow Limited, UK)
210was added to the samples in 1:1 (v/v) buffer-to-sample ratio.
211Protein molecular weight markers (10–220 KDa, Geneﬂow Limited,
212UK) and BSA were used as controls. 25 ml of sample per well were
213loaded and the gel was run for approximately 2.5 h at a voltage of
214100 V with Tris-Glycine-SDS PAGE buffer (10) (Geneﬂow Limited,
215UK). The gel was stained with colloidal coomassie blue and then
216destained in distilled water overnight. An image of the gel was
217scanned on a gel scanner (GS-700 Imaging Densitometer, Bio-Rad)
218equipped with Quantity One software.
2192.9.2. Circular dichroism
220Circular dichroism (CD) was employed to study the secondary
221structure of BSA. The CD spectra of BSA standard (control) and BSA
222released from NPs after 48 h were collected using a J-815 spec-
223tropolarimeter (Jasco, UK) at 20 C as previously described
224(Greenﬁeld, 2007). The ﬁnal spectra was an average of ﬁve scans
225obtained at a scan speed of 50 nm min1 using a 10 mm path-
226length cell, 260–180 nm wavelength range with a data pitch of
2270.5 nm and band width of 1 nm. The baseline acquired in the
228absence of sample was subtracted for the spectra of all samples
229(Henzler Wildman et al., 2003) and the secondary structure then
230analysed using the CDSSTR method from the DichroWeb server
231(Whitmore and Wallace, 2004; Whitmore et al., 2010).
2322.9.3. BSA activity
233The esterolytic activity of BSA was investigated using 4-
234nitrophenyl acetate esterase substrate as described by Abbate
235et al. (Abbate et al., 2012). Brieﬂy, 1.2 ml of 50 mg/ml of released
236BSA from NCMPs (see Section 2.8) in PBS buffer was added to 15 ml
237of a freshly prepared solution of 5 mM 4-nitrophenyl acetate in
238ACN and incubated for 1 h using a HulaMixerTM Sample Mixer.
239After 1 h, the absorbance was measured at 405 nm. Standard BSA
240(50 mg/ml) and PBS buffer were used as positive and negative
241controls respectively. The ratio of absorbance between the released
242BSA and standard BSA was calculated as the relative residual
243esterolytic activity, with the activity of standard BSA considered to
244be 100%.
2452.10. Determination of the aerosol properties of NCMPs using next
246generation impactor
247The aerosol properties of the spray-dried formulations were
248determined using a Next Generation Impactor, NGI (Copley
249Scientiﬁc Limited, UK). Four capsules of hydroxypropyl methylcel-
250lulose, HPMC, were loaded to contain 12.5 mg of BSA adsorbed
251cationic NPs/NCMPs spray-dried powder (equivalent to 5 mg of
252NPs), and placed in a Cyclohaler1 (Tevapharma). The samples were
253drawn into the NGI at a ﬂow rate of 60 l/min for 4 s, and collected
254using a known volume of 2% SDS in HPLC grade water, and left on a
255shaker for 48 h for the BSA to be released from the NCMPs. The
256samples were centrifuged and the amount of BSA deposited was
257analysed using a micro BCA protein assay kit. The ﬁne particle
258fraction (FPF, %) was determined as the fraction of emitted dose
259deposited in the NGI with dae< 4.46 mm, the mass median
260aerodynamic diameter (MMAD) was calculated from log-proba-
261bility analysis, and the ﬁne particle dose (FPD) was expressed as
262the mass of drug deposited in the NGI, dae< 4.46 mm (n = 3). In
263addition, the percentage (%) deposition was calculated as the
264percentage ratio of the amount of BSA collected in a stage to that of
265the total amount of BSA collected from all stages.
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266 2.11. Cell viability study
267 The in vitro cytotoxicity of the cationic NPs and NPs/NCMPs was
268 evaluated using the MTT assay. A549 cells were cultured in RPMI-
269 1640/10% fetal calf serum/1% antibiotic/antimycotic medium.
270 100 ml (2.5 105 cells/ml) of cell suspension were seeded in 96-
271 well plates and placed in an incubator at 37 C for 24 h
272 supplemented with 5% CO2. This was followed by the addition
273 of 100 ml freshly prepared NPs or NPs/NCMP dispersions in
274 medium at various concentrations (0–312.5 mg/ml) (n = 3) with
275 10% dimethyl sulfoxide (DMSO) as a positive control. Following
276 24 h incubation, 40 ml of a 5 mg/ml MTT solution in PBS was added
277 to each well and incubated for 2 h at 37 C. The medium was
278 removed and replaced with DMSO (100 ml) to dissolve the
279 formazan crystals. The absorbance was measured at 570 nm using
280 a plate reader (Molecular Devices, SpectraMAX 190). The
281 percentage of viable cells in each well was calculated as the
282 absorbance ratio between nanoparticle-treated and untreated
283 control cells.
284 2.12. Statistical analysis
285 All statistical analysis was performed using Minitab1 16 Statis-
286 tical Software and signiﬁcant differences between formulations
287 were assumed at p < 0.05. One-way analysis of variance (ANOVA)
288 with the Tukey’s comparison was employed for comparing the
289 formulations with each other. All values are expressed as their
290 Mean  SD.
291 3. Results
292 3.1. Preparation and characterization of nanoparticles
293 The addition of a cationic surfactant, DMAB, at 1% w/w to the
294 organic solvent during particle formulation produced no signiﬁ-
295 cant difference in particle size and PDI whereas the surface charge
296 changed from negative to positive, as shown in Table 1. Moreover,
297 with an increase in the concentration of DMAB, from 1 to 2% w/w,
298 the particle size of NPs decreased accompanied by an increase in
299 surface charge. However, it was observed that after two washes
300 (centrifugation) the surface charge had decreased with an increase
301 in particle size (Table 1) for all concentrations of DMAB.
302 The TEM images of NPs indicated that the NPs appeared to be
303 smooth and spherical in shape with no visible aggregation or
304 adhesion between NPs (Fig. 1a & b).
305 3.2. Protein adsorption and quantiﬁcation
306 The average adsorption of BSA onto cationic NPs, as shown in
307 Fig. 2a, signiﬁcantly increased from a NP:BSA ratio of 100:4
308 (10.01 1.19 mg per mg of NPs), 100:7 (33.70  3.25 mg per mg of
309 NPs), 100:10 (54.04 1.66 mg per mg of NPs), 100:12
310 (64.10  4.05 mg per mg of NPs), 100:16 (79.54  0.57 mg per mg
311of NPs) to 100:20 (91.29  3.66 mg per mg of NPs) (p < 0.05,
312ANOVA/Tukey’s comparison; all values are signiﬁcantly different to
313each other).
314Table 2 lists the particle size, PDI and zeta-potential of cationic
315NPs with and without BSA adsorbed. Here, the NPs without BSA
316adsorption were treated same as the NPs with BSA adsorption, and
317both these preparations were subjected to three centrifugation
318steps. An additional centrifugation step was necessitated to
319remove the unbound BSA after adsorption. The signiﬁcant increase
320(p < 0.05, ANOVA/Tukey’s comparison) in particle size of NPs
321accompanied with a change in the surface charge was ascribed to
322the adsorption of BSA onto NPs as conﬁrmed using confocal
323microscopy (Section 3.4, Fig. 2b).
3243.3. Characterization of Nanocomposite Microparticles
3253.3.1. Yield, particle size, morphology and moisture content
326A reasonable yield of spray drying, 44.82  4.12% for the empty
327cationic NPs/NCMPs and 48.00  5.66% for BSA adsorbed cationic
328NPs/NCMPs was obtained.
329The size of the NPs after dispersion in water for SD empty
330cationic NPs/NCMPs was 216.50  25.45 nm and PDI 0.276  0.034,
331and for BSA adsorbed cationic NPs/NCMPs was 356.73  33.83 nm
332and PDI 0.467  0.116, conﬁrming the re-dispersion of NPs from
333NCMPs after the microcarrier, L-leu, is dissolved.
334A scanning electron micrograph (Fig. 1c & d) of the NCMPs
335revealed the irregular shape and corrugated surface texture. In
336addition, the size of the NCMPs calculated from the SEM pictures was
337found to be approximately 2.09  0.16 mm, based on an average of
338ﬁve SEM images with 60 individual NCMPs in each of them.
339The analysis of the thermograms obtained using TGA showed
340that the dry powder formulation had a residual moisture content of
3410.46  0.01% w/w indicating the drying employed during the SD
342process was efﬁcient.
3433.4. Characterization of BSA and nanoparticle association
344Confocal microscopy was used to visualise the association of
345BSA with NPs. The confocal images (Fig. 2b), reveal that the red and
346green colours representing NPs and FITC-BSA respectively were
347present simultaneously, indicating their association. In addition,
348the increase in particle size observed after adsorption of BSA onto
349PGA-co-PDL NPs also conﬁrms their association (Table 2).
3503.5. In vitro release studies
351In vitro release studies were performed on protein adsorbed NPs/
352NCMPs and reported as cumulative percentage BSA released over
353time (Fig. 3). An initial burst release, recorded at ‘0’ time point, of
35422.45  2.39% BSA was observed followed by continuous release up
355to 5 h, with BSA release of 73.74  6.60%. After this time period, a
356slow continuous release was observed with release of 88.85  4.38%
357over 48 h.
Table 1
The average particle size Q4and surface charge of nanoparticles (NPs) prepared using different concentrations of surfactant, DMAB (Mean  SD, n = 3).
Concentration of DMAB (% w/w) 0 1 2
Before centrifugation
Z-Average size (nm) 162.23  06.80 175.74  15.46 128.64  06.01
Surface charge (mV) 10.28  01.00 +13.24  08.00 +42.32  02.70
After centrifugationa
Z-Average size (nm) 463.52  23.69 710.7 1  152.66 223.08  05.60
Surface charge (mV) 19.14  01.08 10.86  00.84 +35.94  01.36
The PDI values of all samples were in the range of 0.1–0.2 (before centrifugation) and 0.2–0.3 (after centrifugation).
a After centrifugation size and charge was determined after two centrifugation runs.
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358 3.6. Protein stability and activity
359 The primary structure of BSA released from cationic NPs/NCMPs
360 after 48 h was analysed using SDS-PAGE. As shown in Fig. 4a,
361 standard BSA displays a white band (lane 2) adjacent to the MW
362 standards (lane 1). In addition, the bands for released BSA from
363 cationic NPs/NCMPs (lane 3–5) are identical to that of the standard
364 BSA indicating its stability during and after the SD process.
365 Conformational changes of BSA released from NPs were
366 determined by CD spectroscopy. The CD spectra of standard BSA
367 and the BSA released are shown in Fig. 4b. As expected, the spectra
368 show minima at 208–210 and 221–222 nm characteristic of
369 a-helical structure. The data for the spectra as presented in
370 Table 3, showed that the predominant structure of BSA was helical
371 displaying 51 and 43% helicity for standard BSA and BSA released,
372 respectively. In addition, the spectral data obtained for standard
373 BSA were in good agreement with previous reports (Norde and
374 Giacomelli, 2000; Zhang et al., 2010).
375 The esterolytic activity of BSA released from cationic NPs/
376 NCMPs was investigated using 4-nitrophenyl acetate esterase and
377 was calculated to be 78.76  1.54% relative to standard BSA.
378 3.7. Aerosol properties of NCMPs
379 The percentage mass of BSA recovered from the NGI was
380 approximately 83%, well within the pharmacopeial limit of 75–
381 125% of the average delivered dose (2.9.18. Preparations for
382Inhalation: Aerodynamic Assessment of Fine Particles., 2010). The
383deposition data obtained from spray-dried formulations displayed
384a FPD of 16.57  0.74 mg (per capsule of 12.5 mg), FPF of
38570.67 4.07% and MMAD of 2.80  0.21 mm suggesting that the
386formulation was capable of delivering efﬁcient BSA to the
387bronchial-alveolar region of the lungs. The percentage stage wise
388deposition of BSA in NGI is represented in Fig. 5.
3893.8. Cell viability study
390The cytotoxicity of cationic NPs and NCMPs was assessed by the
391MTT assay on A549 cells. The cationic NPs and NCMPs (Fig. 6)
392indicated a decrease in cell viability with an increase in concentra-
393tion. The particles showed a cell viability of 74.55 12.29% (NPs),
39495.07  14.50% (NCMPs) at 78.12 mg/ml concentration that reduced
395to 50.50  9.41% (NPs), 75.76  03.55% (NCMPs) at 156.25 mg/ml
396concentration after 24 h exposure. Above 156.25mg/ml concentra-
397tion, the NPs and NCMPs showed cell survival less than 50%.
3984. Discussion
399Surfactants are often employed in the NP preparation process to
400increase the physical stability and decrease agglomeration
401(Bhardwaj et al., 2009). Herein, the cationic surfactant, DMAB,
402was employed to prepare positively charged NPs and its use as a
403surfactant in preparing cationic NPs has been previously reported
404in the literature (Chen et al., 2010; Hariharan et al., 2006; Kwon
Fig. 1. Transmission electron microscope image of cationic NPs formulated with 2% w/w DMAB stabilizer (a) 44,000X (scale – 200 nm) and (b) 110,000X (scale – 100 nm).
Scanning electron microscope images of cationic NPs/NCMPs (c) 5 mm and (d) 2 mm.
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405 et al., 2001; Mei et al., 2009). In this study, we investigated the
406 effect of surfactant concentration on the particle size and charge of
407 NPs. It was observed that with an increase in the concentration of
408 DMAB, the NP particle size decreased accompanied with an
409 increase in surface charge. The smaller size achieved at the higher
410 concentration of surfactant was due to the broad presence of the
411 surfactant at the o/w interface as reported by Bhardwaj et al.
412 (Bhardwaj et al., 2009). The DMAB concentration of 2% w/w
413 produced positively charged NPs of the smallest size,
414 128.64  06.01 nm. Similar results showing DMAB altering particle
415 size and surface charge have been reported by others (Bhardwaj
416 et al., 2009; Chen et al., 2010; Hariharan et al., 2006; Kwon et al.,
417 2001). However, after centrifugation the particle size had increased
418 at all cationic surfactant concentrations used accompanied with a
419 decrease in surface charge. This was because of the removal
420 (washing away) of surfactant during the centrifugation process
421 that lead to agglomeration of NPs, due to insufﬁcient covering of
422particles. The washing step is necessary so as to ensure the removal
423of excess or unbound surfactant from NPs (as excessive surfactant
424can be harmful for delivery). In addition, the washing removed the
425surfactant coating on the particles resulting in reduced surface
426charge. Moreover, the NPs (0% DMAB surfactant) have a smaller
427particle size (463 nm) compared to the 1% DMAB surfactant
428(710 nm). The reason for this is that the surfactant shown in Table 1
429was only cationic DMAB surfactant; however, all the NPs have PVA
430as an additional surfactant. This may be the reason that we see
431such a difference in size. The PVA surfactant along with 1% DMAB
432cationic surfactant is causing some interactions and leading to an
433increase in particle size of NPs. At 0% DMAB, the PVA is providing
434some stability and repulsion between particles. However at 1%
435DMAB there is interaction between +ve DMAB and PVA, hence
436some particles maybe +ve others –ve after washing, hence the
437aggregation. At 2% DMAB this dominates the PVA resulting in more
438stable positive particles.
Fig. 2. (a) Amount of BSA adsorbed in mg per Q3mg of nanoparticles (NPs) for different weight ratios of NP:BSA (Mean  SD, n = 3), (b) Confocal microscopic image, split view, of
spray-dried NCMPs containing the ﬂuorescent nanoparticles (red, labeled using nile red dye) adsorbed with FITC-BSA (green); *p < 0.05, ANOVA/Tukey’s comparison. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 2
Particle size, PDI and zeta-potential of cationic nanoparticles (NPs) with and without BSA adsorption (Mean  SD, n = 3).
NP suspensionsa Without BSA adsorptionb With BSA adsorptionc
Particle size (nm) 128.64  06.01* 234.65  10.25* 348.36  14.02*
PDI 0.099  0.016 0.200  0.010 0.266  0.006
Zeta-potential (mV) +42.32  02.70 +20.50  0.17 01.44  0.18
a, b and c were subjected to three centrifugation steps, * p < 0.05, ANOVA/Tukey’s comparison.
a NPs characterized immediately after preparation without centrifugation.
b NPs characterized after centrifugation but without adsorption of BSA.
c NPs characterized after centrifugation and BSA adsorption, 2% cationic surfactant, DMAB, was used for this experiment.
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439 The adsorption of proteins onto polymeric NPs is believed to be
440 dominated by hydrophobic, electrostatic interactions and hydro-
441 gen bonding (Yoon et al., 1999). Here, we investigated the effect of
442 BSA adsorption onto the polymeric DMAB-modiﬁed cationic NPs
443 wherein the BSA is negatively charged (Regev et al., 2010). The
444 adsorption of BSA onto the cationic NPs increased signiﬁcantly
445 with an increase in the loading concentration of BSA. This was
446 because more BSA was available for binding and this further
447 suggests the dominance of electrostatic interactions between the
448 BSA and cationic NPs. In addition, the adsorption of BSA onto the
449 surface of cationic NPs was conﬁrmed by an increase in the particle
450 size of NPs after adsorption accompanied with a change in surface
451charge from positive to nearly neutral. Once the protein is
452adsorbed onto the NP, the protein will orientate itself for maximum
453stability on the surface of the NPs and only expose certain amino
454acids to the environment resulting in the change in surface charge
455(Yoon et al., 1999). In addition, the adsorption of BSA was
456characterized by confocal microscopy which indicated the
457association of BSA molecules with the cationic NPs. Similarly, Li
458et al. recently showed that adsorption of negatively charged
459ovalbumin onto positively charged aluminium hydroxide NPs was
460mainly driven by electrostatic interactions (Li et al., 2014). Besides,
461achieving higher adsorption at lower concentrations of added
462protein, reduces the amount of NPs required to be delivered and for
463expensive recombinant proteins reduces the amount of initial
464protein required thereby reducing the cost of the ﬁnal product.
465The NCMPs were produced by SD using L-leu as a microcarrier.
466The NCMPs containing the cationic NPs had a rough surface and
467were irregularly shaped. These rough and wrinkled surface
468characteristics are typical for NCMPs produced using L-leu as an
469excipient and have been widely reported in the literature (Kunda
470et al., 2014; Li et al., 2005; Najafabadi et al., 2004; Rabbani and
Fig. 3. In vitro release proﬁle for BSA from NPs in phosphate buffer saline, pH 7.4 (Mean  SD, n = 3).
Fig. 4. (a) SDS-PAGE of Lane 1: molecular weight standards, broad range (Bio-Rad Laboratories, Hercules CA, USA), Lane 2: Standard BSA, Lane 3, 4 and 5: Released BSA from
cationic NPs/NCMPs after 48 h. (b) CD spectra of standard BSA (black) and BSA released (grey).
Table 3
The percentages of the secondary structures of standard, supernatant and released
BSA samples (Mean  SD, n = 3).
Sample Helix Strand Turns Unordered
Standard BSA 51.0  0.007 21.1  0.070 06.0  0.010 18.0  0.007
BSA released 43.0  0.021 29.5  0.007 07.0  0.000 21.0  0.000
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471 Seville, 2005; Seville et al., 2007; Sou et al., 2013; Tawfeek et al.,
472 2011; Tawfeek et al., 2013). L-leu is a weak surfactant and it has
473 been established in the literature that L-leu spray-dried particles
474 have a low density are capable of forming a shell thereby
475 encapsulating the particles within (Kunda et al., 2014; Lucas
476 et al., 1999; Najafabadi et al., 2004; Tawfeek et al., 2011; Tawfeek
477 et al., 2013; Vehring, 2008).
478 The identical bands obtained on SDS-PAGE for standard BSA and
479 released BSA conﬁrmed the stability of protein during the
480 adsorption and SD process. The CD spectral data further conﬁrmed
481 the presence of a-helix (43%) though slightly less than the
482 standard BSA (51%). The slight decrease observed could be due to
483 the adsorption and desorption process of the protein with the NPs.
484 In addition, the released BSA retained 78% of relative residual
485 esterolytic activity compared to standard BSA. This reduction in
486 activity was expected due to a decrease observed in helicity as
487 determined by CD and could also be because of the adsorption and
488 desorption process of BSA onto NPs. A similar reduction in activity
489 of BSA to 60% when released from hydrogels was observed by
490 Abbate et al. (Abbate et al., 2012).
491 The aerosol properties of the SD formulation predict an
492 effective delivery to the deep lungs via inhalation. The FPF and
493MMAD values suggest an excellent aerosolisation performance and
494deep lung deposition proﬁle in the bronchial-alveolar region of the
495lungs (Kunda et al., 2013). The corrugated surface of the NCMPs
496produced reduces contact points between particles leading to an
497improved aerosolisation performance (Feng et al., 2011; Sou et al.,
4982013). The enhanced aerosolisation performance of formulations
499containing L-leu has been previously reported by others (Li et al.,
5002005; Najafabadi et al., 2004; Sou et al., 2013).
501The residual moisture content in the spray-dried NCMPs
502formulations induces aggregation and leads to variation in size
503distribution (Anish et al., 2014). In addition, higher moisture
504content affects the stability of the formulation and the aerosolisa-
505tion properties resulting in poor deposition with subsequent
506reduction of NPs release in the bronchiole-alveolar region. The
507moisture content obtained here was low (0.5%) which could be
508due to the hydrophobicity of L-leu.
509The DMAB-modiﬁed cationic NPs were relatively toxic at high
510concentrations; however, the probability of achieving such high
511local concentrations in the lungs can be excluded as reported by
512Bhardwaj et al., as the deposited dose would be distribute
513throughout the lungs (Bhardwaj et al., 2009). One drawback that
514is often associated with cationic molecules is their cytotoxicity that
Fig. 5. The percentage deposition of BSA by stage-wise in NGI (Mean  SD, n = 3).
Fig. 6. A549 cell viability measured by MTT assay after 24 h exposure to cationic NPs and NCMPs (Mean  SD, n = 3); Cationic NPs/NCMPs and Cationic NPs.
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515 limits the dosage to be administered to a minimum thereby
516 resulting in low efﬁciency (Kwon et al., 2005). Fischer et al.
517 reported that cationic particles made of different polymers, caused
518 toxicity upon interaction with the negatively charged cell
519 membrane surface. Besides, it was also noted that the magnitude
520 of the cytotoxicity of different polymers were highly dependent on
521 the length and concentration of exposure (Fischer et al., 2003). In
522 addition, Harush-Frenkel et al. reported that cationic NPs caused
523 more toxicity compared to anionic NPs (Harush-Frenkel et al.,
524 2008). However, in the case of DMAB-modiﬁed cationic PGA-co-
525 PDL NPs, a high adsorption of BSA onto NPs can be achieved thus
526 requiring a low dosage of NCMPs containing cationic NPs to be
527 administered which will address the toxicity concerns. The results
528 obtained above suggest further exploration for use of DMAB-
529 modiﬁed cationic PGA-co-PDL NPs for delivery of proteins via
530 inhalation.
531 5. Conclusions
532 The DMAB-modiﬁed cationic PGA-co-PDL NPs were successful-
533 ly produced by single emulsion solvent evaporation method. The
534 adsorption of BSA onto the cationic NPs increased with increasing
535 concentrations of BSA due to opposite charges. The BSA adsorbed
536 NPs were successfully spray-dried into NCMPs using L-leu as a
537 microcarrier producing a yield of 48.00  5.66% with the NCMPs
538 having an irregular and wrinkled surface morphology. The BSA
539 released from the NCMPs was shown to largely maintain its
540 structure under SDS-PAGE and CD analysis with 78% relative
541 esterolytic activity remaining. Moreover, the FPF of 70.67 4.07%
542 and MMAD of 2.80  0.21 mm values indicate deep lung deposition
543 in the bronchial-alveolar region. The results obtained above with
544 regards to NP formulation, protein stability and good aerosolisa-
545 tion performance indicate a good potential and encourage more
546 investigation for applications of these materials for pulmonary
547 drug delivery.
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